Evoke Pharma Inc represents strong values and embraces a corporate philosophy focused on innovation, patient care, and delivering breakthrough solutions in the pharmaceutical industry. With a steadfast commitment to research and development, Evoke Pharma strives to develop novel therapies that address unmet medical needs. By prioritizing collaboration and maintaining high ethical standards, the company aims to provide patients with effective treatment options. Evoke Pharma Inc consistently seeks to improve healthcare outcomes, enhance patient experiences, and create long-term value for shareholders.

Evoke Pharma Inc is primarily present in the United States.

Evoke Pharma Inc has achieved significant milestones. This pharmaceutical company specializes in developing innovative therapies for gastrointestinal disorders. Some of their notable accomplishments include the successful FDA approval of their product EVK-001, a nasal spray for the treatment of diabetic gastroparesis. Additionally, they have forged strategic partnerships with leading healthcare organizations to advance research and development efforts. Evoke Pharma Inc continues to make strides in improving patient care and addressing unmet medical needs in the field of gastrointestinal disorders.

Evoke Pharma Inc is a pharmaceutical company that specializes in developing innovative therapies for gastrointestinal disorders. Founded in 2007, the company is based in San Diego, California. Evoke Pharma is dedicated to improving patient outcomes by addressing unmet medical needs through its proprietary delivery technologies. With a strong focus on developing treatments for diabetic gastroparesis, a condition characterized by delayed gastric emptying, Evoke Pharma aims to provide effective solutions for patients worldwide. The company has made significant strides in advancing its product pipeline and collaborating with key partners to bring these much-needed therapies to the market.

The main competitors of Evoke Pharma Inc in the market include companies such as Johnson & Johnson, Pfizer, Novartis, GlaxoSmithKline, and AstraZeneca.

Evoke Pharma Inc is primarily active in the pharmaceutical industry.

The business model of Evoke Pharma Inc is focused on developing and commercializing innovative therapies for gastrointestinal diseases. The company primarily focuses on the development of EVK-001, a patented nasal spray formulation of metoclopramide, which is intended to treat symptoms associated with diabetic gastroparesis. Evoke Pharma Inc aims to provide a safe and effective treatment option to patients suffering from this condition. By leveraging its expertise in drug development and commercialization, Evoke Pharma Inc endeavors to improve the quality of life for individuals with gastrointestinal disorders.

Evoke Pharma KGV ir -0,05.

Evoke Pharma KUV ir 0,09.

AlleAktien kvalitātes vērtējums Evoke Pharma ir 6/10.

gaidāmā Evoke Pharma apgrozījums ir 11,61 milj. USD.

gaidāmā Evoke Pharma peļņa ir -21,23 milj. USD.

Evoke Pharma Inc is a biopharmaceutical company focused on developing innovative solutions for unmet medical needs. The company specializes in the development and marketing of therapeutics to improve the lives of patients. The company has two main divisions: product development and marketing. The emphasis of product development is on developing new drugs, with a focus on gastrointestinal (GI) diseases. The company's goal is to create products that are more effective than current market offerings. One of the company's key products is Gimoti, which is used to treat nausea and vomiting in adults with gastroparesis. Gimoti is a dopamine receptor antagonist and the first oral spray approved by the FDA for gastroparesis treatment. Evoke Pharma Inc aims to strengthen the market position and awareness of Gimoti while expanding its product portfolio. The company collaborates with the FDA to explore additional uses for Gimoti and meet more medical needs. Evoke Pharma Inc follows an innovative business model, emphasizing collaboration with leading medical institutions and experts in the field of GI diseases. The company conducts extensive research and development to expand its product pipeline and strengthen its market position. It also employs a comprehensive marketing strategy, utilizing social media as an important sales channel to provide relevant and timely information to its target audience. Overall, Evoke Pharma Inc offers an innovative approach to the development and marketing of products for GI diseases. The company has released Gimoti, a promising product, and is expected to launch more products in the near future to improve the lives of patients with unmet medical needs.

Evoke Pharma izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Evoke Pharma vai uzņēmums nedod dividendes.

Evoke Pharma ISIN ir US30049G1040.

Evoke Pharma WKN ir A1W6DP.

Evoke Pharma simbols ir EVOK.

Pēdējo 12 mēnešu laikā Evoke Pharma maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Evoke Pharma plāno maksāt dividendes 0 USD apmērā.

Evoke Pharma pašreizējā dividendu rentabilitāte ir .

Evoke Pharma maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Evoke Pharma pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Evoke Pharma tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Evoke Pharma apmērā 0 USD, kas tika izmaksāta 9.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 9.09.2024..

Pēdējās dividendes izmaksa notika 9.09.2024..

Gadā 2023, Evoke Pharma izmaksāja 0 USD dividendes.

Evoke Pharma dividendes tiek izmaksātas USD.